Clinical evidence strategy for diagnostics and medical devices
Abingdon AI & MedTech
Clinical trial and performance evaluation strategy
The quality of a product’s evidence package often determines how smoothly the regulatory process progresses. Weak study design, incomplete evidence or unclear justification can create delays long before a regulator reviews a submission. Abingdon AI & MedTech helps manufacturers develop evidence strategies that stand up to scrutiny and support successful market access, while meeting MDR, IVDR, FDA and UK regulatory requirements.
Across the lifecycle
Supporting Clinical and Performance Evaluation Activities
Evidence generation does not stop when a study finishes. Regulatory expectations continue throughout the product lifecycle, requiring manufacturers to review emerging data, maintain clinical justification and respond to evolving requirements. Our team supports these activities throughout development, approval and post-market use.
What we deliver
Clinical strategy services
Protocol Design Advisory
Decisions made during study design can have a lasting impact on regulatory outcomes. We help manufacturers establish study approaches that generate meaningful evidence, answer regulatory questions and support future product claims. We help manufacturers develop study protocols that align with regulatory expectations while supporting product claims and commercial objectives.
IRB / IEC and Competent Authority Submissions
Preparing submissions for ethics committees and regulatory authorities requires detailed planning and documentation. Abingdon AI & MedTech supports the preparation and coordination of IRB, IEC and Competent Authority applications, helping organisations navigate approval processes efficiently while ensuring regulatory requirements are met before study initiation.
Clinical Study Report Writing
A study only creates value if its findings are communicated clearly. We help manufacturers transform complex study results into documentation that regulators can review efficiently and confidently, by turning study data into submission-ready documentation that supports regulatory approval and market access.
Our approach
Why Abingdon AI & MedTech?
Clinical evidence requirements vary significantly between technologies, indications and intended uses. Our team brings experience across diagnostics, medical devices and emerging healthcare technologies, helping organisations build evidence strategies that are proportionate, defensible and aligned with regulatory expectations.
From the Knowledge Centre
Read more on Clinical trial and performance evaluation strategy
Practical guidance from the specialists who deliver this work every day.
Article
Performance Evaluation for FDA 510(k): Building Your Substantial Equivalence Case
What FDA 510(k) performance evaluation requires and how to build a strong case for substantial equivalence in IVD submissions.
Also worth reading
- Article Performance Evaluation: the critical product-to-market component
-
Article
Understand LFT IVDR Performance Evaluation Changes: Protect Your Test And Business
-
Article
Clinical Trials with Lateral Flow Tests: Key Considerations
-
Article
Companion Diagnostics: Playing 5D Chess in Regulatory Development
Case study
Find Out From Home STD Tests Development Project
How Abingdon Health partners with Find Out From Home (FOFH) to develop and commercialise rapid sexually transmitted disease self-tests.
Frequently asked questions
Clinical and performance evaluation FAQs
A Clinical Evaluation Report (CER) documents the assessment of clinical evidence supporting a medical device’s safety and performance. Under MDR, it forms a key part of the technical documentation reviewed during conformity assessment.
A performance evaluation demonstrates that an IVD delivers the scientific validity, analytical performance and clinical performance required for its intended use. It is a core requirement for IVDR compliance and market access.
Not always. The requirement depends on the product, its intended purpose and the strength of the existing evidence available to support regulatory approval.
A clinical evidence strategy defines how safety, performance and clinical benefit will be demonstrated throughout product development and regulatory review. Establishing this strategy early can help avoid evidence gaps and support smoother submissions under FDA, MDR and IVDR frameworks.
Support may include protocol design, performance evaluation planning, ethics submissions, clinical study reporting and evidence gap assessments. The focus is on generating evidence that can withstand regulatory scrutiny and support product approval.
Start the conversation
Planning a clinical or performance study?
Whether you need support with protocol development, ethics submissions, performance evaluations or clinical reporting, Abingdon AI & MedTech can help. Speak with our specialists to develop a clinical evidence strategy that supports regulatory approval and successful market access.
- US, EU and UK market access
- ISO 13485, MDR, IVDR and FDA expertise
- Flexible support models